Is aspirin effective in diabetic patients? Yes

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 12, 2005, Pages 2612-2614

  Colwell, J A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SHORT SURVEY;

ASPIRIN; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; TREATMENT OUTCOME;

EID: 29244491679     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01719.x     Document Type: Short Survey

References (29)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Colwell JA, Jokl R. Vascular thrombosis in diabetes. In: Porte D, Sherwin R, Rifkin H, eds. Diabetes Mellitus: Theory and Practice, 6th edn. Norwalk (CT): Appleton & Lange, 1996: 207-16.
3. Ostermann H, Van de Loo J. Factors of the hemostatic system in diabetic patients: a survey of controlled studies. Haemostasis 1986; 16: 386-416.
4. Jokl R, Colwell JA. Clotting disorders in diabetes. In: Alberti KGMM, Zimmet P, De Fronzo R, Keen H, eds. International Textbook of Diabetes Mellitus, 2nd edition. Chichester, UK: John Wiley & Sons Ltd, 1997: 1543-57.
5. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycemia and therapeutic prospects. Diabetologia 1993; 34: 457-62.
6. Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 1975; 82: 733-8.
7. Colwell JA, Nair RM, Halushka PV, Rogers C, Whetsell A, Sagel J. Platelet adhesion and aggregation in diabetes mellitus. Metabolism 1979; 28: 394-400.
8. Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JG. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 1972; 80: 236-46.
9. Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract 2000; 50: 1-16.
10. Halushka PV, Rogers RC, Loadholdt CB. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 1981; 97: 87-96.
11. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type-II diabetes mellitus. N Engl J Med 1990; 322: 1769-74.
12. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
13. DeMinno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986; 68: 886-91.
14. Albert SG, Hasnain BI, Ritter OG, Joist JH, Mooradian AD. Aspirin sensitivity of platelet aggregation in diabetes mellitus. Diab Res and Clin Pract 2005; 70: 195-99.
15. Stamler JM, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
16. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
18. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med 1989; 321: 129-35.
19. ETDRS Investigators. Aspirin effects on mortality and morbidity in prints with diabetes mellitus. JAMA 1992; 268: 1292-300.
20. Hansson L, Zanchetti A, Carruthers SG, Dahlof D, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedal H, Westerling S for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.
21. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 357: 89-95.
22. Sacco M, Pellegrini F, Roncaglioni MC, Venzini F, Tognoli G, Nicolucci A on behalf of the PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care 2003; 26: 3264-72.
23. Colwell JA. Aspirin therapy in diabetes. Diabetes 1997; 20: 1767-71.
24. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004; 27: S72-3.
25. AHA Scientific Statement. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 up date. Circulation 2002; 106: 288-91.
26. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: summary of the evidence. Ann Intern Med 2002; 136: 161-72.
27. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004; 25: 166-81.
28. Stevens RJ, Kothari V, Adler A, Stanton IM, Holman R. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS56). Clin Sci 2001; 101: 671-79.
29. Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of the UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine 2004; 21: 238-45.